23 May 2013
Keywords: bi, baminercept, enters, ph, iib, trials, drugmaker
Article | 19 November 2007
US drugmaker Biogen Idec presented strong results from a Phase IIa trial of baminercept (LT(beta)R-Ig or BG9924), the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 November 2007
26 November 2007
© 2013 thepharmaletter.com